Bottom Line: Biotech risks
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE TROUBLE with biotechnology stocks is they ask you to take a lot on trust. Celltech, which with its pounds 50m placing and public offer of 20 million ordinary shares at 250p each is raising pounds 30m, does not expect to make a profit until 1997-98.
But if everything goes according to plan - a big if - Lehman Brothers' pharmaceutical research team calculates there should be an average return of about 30 per cent a year.
Broadly speaking there are three ways of valuing these stocks - by comparative market capitalisation relative to number and status of development products, by comparative market capitalisation relative to research and development spending, and on a discounted revenue basis. On all three Celltech's price and pounds 176.5m market capitalisation look reasonable.
But before buying Celltech it is important to understand the risk. In its case Celltech Biologics, the subsidiary manufacturer of monoclonal antibodies - which is profitable, throws a floor under the share price at about 50p a share. But should the septic shock treatment in particular not bear fruit returns would fall sharply.
Serious buyers should hold the shares until the research has proved fruitful or otherwise.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments